Urate crystals induce macrophage PAF‑AH secretion which is differentially regulated by TGFβ1 and hydrocortisone

Yagnik,Darshna; Hills,Frank

doi:10.3892/mmr.2018.9323

Urate crystals induce macrophage PAF‑AH secretion which is differentially regulated by TGFβ1 and hydrocortisone

Authors:
- Darshna Yagnik
- Frank Hills
View Affiliations

Affiliations: Department of Natural Sciences, Biomarker Research Group, School of Science and Technology, Middlesex University, The Burroughs, London NW4 4BT, UK
Published online on: July 26, 2018 https://doi.org/10.3892/mmr.2018.9323
Pages: 3506-3512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to establish the role of platelet‑activating factor acetyl hydrolase (PAF‑AH) in the resolution phase of gout using an established in vitro mononuclear cell model. The effects of signalling pathway inhibitors on PAF‑AH secretion, as well as the effects of the common treatments hydrocortisone and colchicine, an antibody against the anti‑inflammatory cytokine transforming growth factor β1 (TGFβ1), and the transcriptional inhibitor actinomycin D, were also investigated. The effect of recombinant PAF‑AH on cytokine secretion by these cells was also determined. Human peripheral blood‑derived monocytes were isolated and differentiated into macrophages. Monocytes and macrophages were stimulated with monosodium monohydrate urate (MSU) crystals or lipopolysaccharide in the presence or absence of AEG3482 [a c‑Jun N‑terminal kinase (JNK) inhibitor], MG132 (a proteasome inhibitor), hydrocortisone or colchicine. Cultures were then analysed for PAF‑AH secretion using ELISA. A 6‑fold upregulation of PAF‑AH secretion was observed following macrophage exposure to MSU crystals for 24 h (29.3±6 vs. 5.4±0.3 ng/ml unstimulated; P<0.05). Following 72 h, PAF‑AH levels decreased significantly (11.1±1.8; P<0.01). Secretion was further enhanced following pre‑treatment with the JNK protein kinase inhibitor AEG3482 prior to MSU crystal stimulation (P<0.05) and was abrogated when cells were preincubated with actinomycin D or the proteasome inhibitor MG132 (50, 100 and 200 µM). The addition of recombinant PAF‑AH (2.5‑10 ng/ml) to MSU crystal‑stimulated immature monocyte cultures significantly decreased pro‑inflammatory interleukin (IL)‑1β (unstimulated 687±124 vs. stimulated 113±30 pg/ml) and IL‑6 secretion (unstimulated 590±50 vs. stimulated 182±19 pg/ml). Treatment of MSU crystal‑stimulated macrophages with hydrocortisone (2 µM) also significantly decreased PAF‑AH release (P<0.05). Neutralising anti‑TGFβ1 addition decreased PAF‑AH dose‑dependently with the highest inhibition observed at 1 µg/ml (P<0.05). The results implicated that PAF‑AH may have an anti‑inflammatory role in the resolution phase of gout.

View Figures

View References

1	Hippocrates: The Genuine Works of Hippocrates. I and II. Adams F: New York: William Wood and Company; 1886
2	Copeman WS: A short history of the gout and the rheumatic diseases. Berkeley and Los Angeles: University of California Press; 1964
3	Kuo CF, Grainge MJ, Mallen C, Zhang W and Doherty M: Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis. 72:661–667. 2015. View Article : Google Scholar
4	di Giovine FS, Malawista SE, Thornton E and Duff GW: Urate crystals stimulate production of tumour necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest. 87:1375–1381. 1991. View Article : Google Scholar : PubMed/NCBI
5	Schiltz C, Lioté F, Prudhommeaux F, Meunier A, Champy R, Callebert J and Bardin T: Monosodium urate monohydrate crystal induced inflammation in vivo: Quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 46:1643–1650. 2002. View Article : Google Scholar : PubMed/NCBI
6	Daoussi D, Andonpoulos I and Andonopoulos AP: ACTH as a treatment for acute crystal induced arthritis: Update on clinical evidence and mechanisms of action. Semin Arthritis Rheum. 43:648–653. 2014. View Article : Google Scholar : PubMed/NCBI
7	Vanja SK, Rathinam VA and Fitzgerald KA: Mechanisms of inflammasome activation: Recent advances and novel insights. Trends Cell Biol. 25:308–315. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yagnik DR, Hillyer P, Marshall D, Smythe CD, Krausz T, Haskard DO and Landis RC: Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout. Arthritis Rheum. 43:1779–1789. 2000. View Article : Google Scholar : PubMed/NCBI
9	Yagnik D: Macrophage derived platelet activating factor implicated in the resolution phase of gouty inflammation. Int J Inflam. 2014:5264962014. View Article : Google Scholar : PubMed/NCBI
10	Landis RC, Yagnik DR, Florey O, Philippidis P, Emons V, Mason JC and Haskard DO: Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum. 46:3026–3033. 2002. View Article : Google Scholar : PubMed/NCBI
11	Yagnik DR, Evans BJ, Florey O, Mason JC, Landis RC and Haskard DO: Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 50:2273–2280. 2004. View Article : Google Scholar : PubMed/NCBI
12	Howard KM, Abdel-Al M, Ditmyer M and Patel N: Lipopolysaccharide and platelet-activating factor stimulate expression of platelet-activating factor acetylhydrolase via distinct signaling pathways. Inflam Res. 60:735–744. 2011. View Article : Google Scholar
13	Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al: 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 76:29–42. 2017. View Article : Google Scholar : PubMed/NCBI
14	Elstad MR, Stafforini DM, McIntyre TM, Prescott SM and Zimmerman GA: Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem. 25:8467–8470. 1989.
15	Narahara H and Johnston JM: Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am J Obstet Gynecol. 169:531–537. 1993. View Article : Google Scholar : PubMed/NCBI
16	Wu X, Zimmerman GA, Prescott SM and Stafforini DM: The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem. 279:36158–36165. 2004. View Article : Google Scholar : PubMed/NCBI
17	Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H and Inoue K: Purification and characterization of platelet-activating factor acetylhydrolase II from bovine liver cytosol. J Biol Chem. 270:22308–22313. 1995. View Article : Google Scholar : PubMed/NCBI
18	Stafforini DM, McIntyre TM, Zimmerman GA and Prescott SM: Platelet-activating factor acetylhydrolases. J BiolChem. 272:17895–17898. 1997.
19	Stafforini DM, Prescott SM, Zimmerman GA and McIntyre TM: Mammalian platelet-activating factor acetylhydrolases. Biochim Biophys Acta. 1301:161–173. 1996. View Article : Google Scholar : PubMed/NCBI
20	Stafforini DM, Prescott SM and McIntyre TM: Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem. 262:4223–4230. 1987.PubMed/NCBI
21	Neto Castro Faria HC, Stafforini DM, Prescott SM and Zimmerman GA: Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase. Mem Inst Oswaldo Cruz. 100 Suppl 1:S83–S91. 2005. View Article : Google Scholar
22	Blank ML, Lee T, Fitzgerald V and Snyder F: A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem. 256:175–178. 1981.PubMed/NCBI
23	Akira S, Misawa T, Satoh T and Saitoh T: Macrophages control innate inflammation. Diabetes Obes Metab. 15 Suppl 3:S10–S18. 2013. View Article : Google Scholar
24	So AK and Martinon F: Inflammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol. 13:639–647. 2017. View Article : Google Scholar : PubMed/NCBI
25	Triggiani M, Granata F, Giannattasio G and Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: Not just enzymes. J Allergy Clin Immunol. 116:1000–1006. 2005. View Article : Google Scholar : PubMed/NCBI
26	Perelman B, Adil A and Vadas P: Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy. Allergy Asthma Clin Immunol. 10:202014. View Article : Google Scholar : PubMed/NCBI
27	Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M, Nojima S and Kudo I: Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J Biol Chem. 272:19708–19713. 1997. View Article : Google Scholar : PubMed/NCBI
28	Vadas P, Browning J, Edelson J and Pruzanski W: Extracellular phospholipase A2 expression and inflammation: The relationship with associated disease states. J Lipid Mediat. 8:1–30. 1993.PubMed/NCBI
29	Miguélez R, Palacios I, Navarro F, Gutierrez S, Sanchez-Pernaute O, Egido J, González E and Herrero-Beaumont G: Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal. 13:35–49. 1996. View Article : Google Scholar : PubMed/NCBI
30	Tjolker LW, Eberhardt C, Unger J, Trong HL, Zimmerman GA, McIntyre TM, Stafforini DM, Prescott SM and Gray PW: Plasma platelet activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem. 270:25481–25487. 1995. View Article : Google Scholar : PubMed/NCBI
31	Gomes RN, Bozza FA, Amâncio RT, Japiassú AM, Vianna RC, Larangeira AP, Gouvêa JM, Bastos MS, Zimmerman GA, Stafforini DM, et al: Exogenous platelet activating factor acetylhyhrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock. 26:41–49. 2006. View Article : Google Scholar : PubMed/NCBI
32	Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 32:332–341. 2004. View Article : Google Scholar : PubMed/NCBI
33	Howard KM and Olson MS: The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem. 275:19891–19896. 2000. View Article : Google Scholar : PubMed/NCBI
34	Li JM, Datto MB, Shen X, Hu PP, Yu Y and Wang XF: Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites. Nucleic Acids Res. 26:2449–2456. 1998. View Article : Google Scholar : PubMed/NCBI
35	Coutinho AE and Chapman KE: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 335:2–13. 2011. View Article : Google Scholar : PubMed/NCBI
36	Zhou G, Marathe GK, Hartiala J, Hazen SL, Allayee H, Tang WH and McIntyre TM: Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2). J Biol Chem. 288:11940–11948. 2013. View Article : Google Scholar : PubMed/NCBI
37	Dandona P, Ghanim H, Sia CL, Green K, Abuaysheh S, Dhindsa S, Chaudhuri A and Makdissi A: A mixed anti-inflammatory and pro-inflammatory response associated with a high dose of corticosteroids. Curr Mol Med. 14:793–801. 2014. View Article : Google Scholar : PubMed/NCBI
38	Guo N and Peng Z: Mg132, a proteasome inhibitor, induces apoptosis in tumour cells. Asia Pac J Clin Oncol. 9:6–11. 2013. View Article : Google Scholar : PubMed/NCBI
39	Dalbeth N, Lauterio TJ and Wolfe HR: Mechanism of action of colchicine in the treatment of gout. Clin Ther. 36:1465–1479. 2014. View Article : Google Scholar : PubMed/NCBI
40	Łuczaj W, Gindzienska-Sieskiewicz E, Jaroka-karpowicz I, Andisic L, Sierakowski S, Zarkovic N, Waeg G and Skrzydlewska E: The onset of lipid peroxidation in rheumatoid arthritis: Consequences and monitoring. Free Radic Res. 50:304–313. 2016. View Article : Google Scholar : PubMed/NCBI
41	Zhang P, Liu J, Tan B, Zhu F and Fang L: Hypercoagulable state is associated with NF-kappa B activation and increased inflammatory factors in patients with rheumatoid arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:364–368. 2016.(In Chinese). PubMed/NCBI